share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A:重大事件(修正)
美股sec公告 ·  05/09 16:38
Moomoo AI 已提取核心訊息
On May 9, 2024, eFFECTOR Therapeutics, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to sell up to $50.0 million of its common stock. The sales may occur on the Nasdaq Capital Market, with the agent receiving a 3.0% commission on gross proceeds. The agreement includes indemnification provisions for the agent and can be terminated by either party with prior written notice. Concurrently, eFFECTOR Therapeutics terminated its previous agreement with Cantor Fitzgerald & Co., under which it had sold over 1 million shares for $9.8 million. The new sales agreement is part of a prospectus supplement to the company's effective registration statement filed with the SEC.
On May 9, 2024, eFFECTOR Therapeutics, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to sell up to $50.0 million of its common stock. The sales may occur on the Nasdaq Capital Market, with the agent receiving a 3.0% commission on gross proceeds. The agreement includes indemnification provisions for the agent and can be terminated by either party with prior written notice. Concurrently, eFFECTOR Therapeutics terminated its previous agreement with Cantor Fitzgerald & Co., under which it had sold over 1 million shares for $9.8 million. The new sales agreement is part of a prospectus supplement to the company's effective registration statement filed with the SEC.
2024年5月9日,Effector Therapeutics, Inc.宣佈與H.C. Wainwright & Co., LLC簽訂市場發行協議,允許該公司出售高達5000萬美元的普通股。銷售可能在納斯達克資本市場上進行,代理商將獲得總收益的3.0%的佣金。該協議包括對代理人的賠償條款,任何一方都可以在事先書面通知的情況下終止。同時,Effector Therapeutics終止了先前與Cantor Fitzgerald & Co. 的協議,根據該協議,該公司以980萬美元的價格出售了超過100萬股股票。新的銷售協議是公司向美國證券交易委員會提交的有效註冊聲明的招股說明書補充文件的一部分。
2024年5月9日,Effector Therapeutics, Inc.宣佈與H.C. Wainwright & Co., LLC簽訂市場發行協議,允許該公司出售高達5000萬美元的普通股。銷售可能在納斯達克資本市場上進行,代理商將獲得總收益的3.0%的佣金。該協議包括對代理人的賠償條款,任何一方都可以在事先書面通知的情況下終止。同時,Effector Therapeutics終止了先前與Cantor Fitzgerald & Co. 的協議,根據該協議,該公司以980萬美元的價格出售了超過100萬股股票。新的銷售協議是公司向美國證券交易委員會提交的有效註冊聲明的招股說明書補充文件的一部分。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息